• 当前位置:网站首页-> 资讯 -> 肺癌知识 -> 医学研究 -> 深度报告

    ASCO2020:肺癌的筛查

    2020-05-14

    3126 0
    作者: 杨学宁 医师

    今年在预防和早诊的主题文章很多。主要都集中在血液中分子特征检测和生物信息学分析上。

    本研究探索了建立无创多分析模型评价肺癌筛查中发现的肺结节。

    A noninvasive multi-analytic approach for lung cancer screening of patients with pulmonary nodules. 

    First Author: Hong Zheng, Department of Thoracic Surgery, Xinqiao Hospital, Chongqing, China

    1550 Poster Session (Board #42), Fri, 8:00 AM-11:00 AM

    Prior to surgery, each patient was also subject to cell-free DNA-based sequencing for DNA mutation and DNA methylation profiling, as well as serum protein biomarker profiling.

    On the 30-patient independent validation cohort, individual prediction models based on clinical information, protein marker, ctDNA mutation, and ctDNA methylation profiles achieved predictive AUC of 0.59, 0.48, 0.71, and 0.84, respectively. The final ensemble model achieved predictive AUC of 0.86, which has strongly indicated that an integrative, algorithmbased approach of multi-analytic molecular and clinical profiles greatly outperforms any single-analytic profiling.

    ctDNA甲基化可以达到AUC 0.84。多分析模型可进一步提高预测?恐怕不是


    今年在预防和早诊的主题中,有关遗传性的研究也不少。但无论是无创性的遗传检测还是早诊,相关的技术还是非常不成熟。然而,无论是国内还是美国,都已有公司在宣传和推广。我担心会是害多而无益,会导致更多恐慌和过度的治疗。这点在国内尤是如此。



    ASCO 2020摘要 

    Cancer Prevention, Risk Reduction, and Genetics

    Developmental Therapeutics—Immunotherapy

    Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

    Lung Cancer— Other Thoracic Cancers

    Lung Cancer—Non-Small Cell Metastatic

    Symptoms and Survivorship


    推荐阅读

    

    文章评论

    注册或登后即可发表评论

    登录/注册

    全部评论(0)